UNASSIGNED: Targeted therapy and immunotherapy in @entity320 have led to a marked improvement in @entity1 ' survival and their quality of life. Although there are data on anti-programmed-death-receptor-1 (anti- @entity8395 ) after ipilimumab, only few data are available on ipilimumab following anti- @entity8395 as the first-line treatment. The aim of our study was to evaluate tolerance and survival of @entity1 treated with ipilimumab as the second-line immunotherapy among @entity320 patients following anti- @entity8395 treatment. Retrospective and descriptive epidemiological studies were carried out at the Dermatology Department of the University Hospital of Lille. We describe a case series of @entity1 treated with ipilimumab after anti- @entity8395 failure for metastatic @entity320 . For each @entity1 , we assessed disease extension since ipilimumab introduction using RECIST 1.1. The time between ipilimumab introduction and other systemic treatment and overall survival (between ipilimumab introduction and last @entity1 visit) was assessed. The effect of ipilimumab after anti- @entity8395 treatment was evaluated in eight @entity1 . Four @entity1 responded to ipilimumab: three showed a complete response and one showed a partial response. For these @entity1 , the time period between the first ipilimumab injection and another systemic treatment ranged from 209 to 391 days and the overall survival ranged from 314 to 581 days. One @entity1 showed grade 3 @entity6519 , an @entity137 with ipilimumab or anti- @entity8395 to our knowledge. We have described the efficacy of ipilimumab following anti- @entity8395 in @entity320 in eight @entity1 . Several comparative studies are still in progress, and their results will be important to develop an optimal therapeutic strategy for our @entity1 .

Ipilimumab in anti- XXXX refractory @entity320 : a report of eight cases.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['unusual toxicity'] @entity6519 :: ('MESH:D002825', 'Disease') :: ['chorioretinitis'] @entity8395 :: ('5133', 'Gene') :: ['PD1'] @entity320 :: ('MESH:D008545', 'Disease') :: ['melanomas', 'metastatic melanoma']
@entity8395 :: (5133,Gene) :: ['PD1']
